Expression level of MEF2C and CEBPA are negatively correlated in the accelerated and blast crisis stages of CML.
Statistical profiling shows that MEF2C, CEBPA and CSF3R are enough to molecularly discriminate CP, AP and BC stages.
Imatinib treatment down-regulates both the mRNA and the protein expression of MEF2C in CML patient sample.